R&D boost much needed & long overdue

The budget's $234 million boost to support business research and development is a “clever” investment that is bound to ripen hefty returns. Brad Duft, president of CoDa Therapeutics, a company operating locally and in the US, told the National Business Review  that New Zealand has tremendous potential in the biotechnology sector as while offering world-class scientists and facilities it is much cheaper to run clinical trials here.
 

Want to read more?

Choose a Subscription type that's right for you HERE
Already have an account? Login